Claim: THC will be removed from drug-test screenings “starting on August 30th.”
Verdict: REFUTES

Retrieved passages:
title: Drug test
text: for up to 12 months. Currently, most entities that use hair testing have prescribed consequences for individuals removing hair to avoid a hair drug test. The claim that a hair test cannot be tampered with has been shown to be debatable. One study has shown that THC does not readily deposit inside epithelial cells so it is possible for cosmetic and other forms of adulteration to reduce the amount of testable cannabinoids within a hair sample. The results of federally mandating drug testing were similar to the effects of simply extending to the trucking industry the right to perform drug

title: Removal of cannabis from Schedule I of the Controlled Substances Act
text: Initiative 502, Washington is one of the first two states to legalize the recreational use of marijuana for individuals over the age of 21. Gary Storck sent a letter to the Controlled Substances board in August 2011 requesting procedures to file a petition, which is discussed at the September 2011 Controlled Substances Board Meeting. The Wisconsin Controlled Substances board has authority to reschedule cannabis pursuant to the rule-making procedures of ch. 227. Drafters plan to submit a petition to the Controlled Substances Board in early 2012. Federal government: Advocacy groups: Removal of cannabis from Schedule I of the Controlled Substances

title: Urban legends about drugs
text: fat cells, leading to a low-grade haze long after the primary high is gone. This myth is based primarily on anecdotal evidence and the known fact that urine drug tests remain positive for at least several days after using, and longer for regular users. The tests however measure non-psychoactive metabolites, not active THC. And the blood levels of THC generally fall well below the psychoactive threshold within 2–4 hours of smoking (4–8 hours after oral use). A cannabis equivalent of a hangover may occur the morning after taking high doses, but even that ends much sooner than the legend suggests.

title: Cannabis and impaired driving
text: to legalize cannabis, "any THC detectable in the body will deem a motorist impaired to drive". Reporting has indicated that blood tests would be utilized. Canadian draft regulations proposed in 2017 (Bill C-46) had summary conviction offences starting at 2 nanograms per milliliter. At the federal level, the United States Department of Transportation regulates public transportation (e.g. pilots, bus drivers, and train operators) and commercial truckers. 49 CFR Part 199 and 49 CFR Part 40 set maximum urine concentration levels of THC-A as the threshold for impairment for regulated transportation occupations. As of January 1, 2018, the THC-A testing cutoffs

title: Cannabis drug testing
text: days up to 10 days according to Redwood Laboratories; heavy users can produce positive tests for 1–3 months after ceasing cannabis use. The length of time varies greatly according to metabolism, quantity, and frequency of use. Marijuana use can be detected up to 3–5 days after exposure for infrequent users; for heavy users: 1–15 days; for chronic users and/or users with high body fat: 1–30 days Under the typical 50 ng/mL cutoff for THC in the United States, an occasional or on-off user would be very unlikely to test positive beyond 3–4 days since the last use, and a chronic

title: Cannabis drug testing
text: user would be unlikely to test positive much beyond 7 days. Using a more sensitive cutoff of 20 ng/mL (less common but still used by some labs), the most likely maximum times are 7 days and 21 days, respectively. In extraordinary circumstances of extended marijuana use, detection times of more than 30 days are possible in some individuals at the 20 ng/mL cutoff. However, every individual is different, and detection times can vary due to metabolism or other factors. It also depends on whether actual THC or THC metabolites are being tested for, the latter having a much longer detection

title: Removal of cannabis from Schedule I of the Controlled Substances Act
text: rescheduled to allow prescription under schedule III. A second petition, based on claims related to clinical studies, was denied in 2001. The most recent rescheduling petition filed by medical cannabis advocates was in 2002, but it was denied by the DEA in July 2011. Subsequently, medical cannabis advocacy group Americans for Safe Access filed an appeal, "Americans for Safe Access v. Drug Enforcement Administration" in January 2012 with the District of Columbia Circuit, which was heard on 16 October 2012 and denied on 22 January 2013. As of August 2018, 30 states and Washington, D.C. have legalized the use of

title: Occupational health concerns of cannabis use
text: invasive blood testing for compounds, under the 4th Amendment of the US constitution. Variability in study designs, ethical dilemma of safety and productivity, work type and drug metabolism in users. When smoked, blood levels of THC immediately rise and are distributed primarily in the lungs and brain. •THC is metabolized to the transient psychoactive substance THC-OH, which is finally converted to THC-COOH, the physiologically inactive metabolite The immediate euphoria and subsequent impairment from THC-OH, as suggested by older studies may last about 6 hours, with some limited studies showing impairment lasting as long as 24 to 48 hours Specific studies

title: Removal of cannabis from Schedule I of the Controlled Substances Act
text: I status. The dispute is based on differing views on both how the Act should be interpreted and what kinds of scientific evidence are most relevant to the rescheduling decision. The Act provides a process for rescheduling controlled substances by petitioning the Drug Enforcement Administration. The first petition under this process was filed in 1972 to allow cannabis to be legally prescribed by physicians. The petition was ultimately denied after 22 years of court challenges, but a synthetic pill form of cannabis's psychoactive ingredient, THC, was rescheduled in 1986 to allow prescription under schedule II. In 1999, it was again

title: Removal of cannabis from Schedule I of the Controlled Substances Act
text: October 9, 2002, the Coalition for Rescheduling Cannabis filed another petition. The new organization consisted of medical cannabis patients and other petitioners who would be more directly affected by the DEA's decision. On April 3, 2003, the DEA accepted the filing of that petition. According to Jon Gettman, "In accepting the petition the DEA has acknowledged that the Coalition has established a legally significant argument in support of the recognition of the accepted medical use of cannabis in the United States." In a footnote to the majority decision in "Gonzales v. Raich", Justice John Paul Stevens said that if the

title: Removal of cannabis from Schedule I of the Controlled Substances Act
text: petitions. Requests have been made to both the DEA and FDA under the Freedom of Information Act to determine the details of that recommendation. On June 23, 2011, Rep. Barney Frank (D-MA), along with 1 Republican and 19 Democratic cosponsors, introduced the Ending Federal Marijuana Prohibition Act of 2011, which would have removed marijuana and THC from the list of Schedule I controlled substances and would have provided that the Controlled Substances Act not apply to marijuana except when transported to a jurisdiction where its use is illegal. The bill was referred to committee but died when no further action

title: Removal of cannabis from Schedule I of the Controlled Substances Act
text: on October 22, 2012, detailing how plaintiff Michael Krawitz was harmed by the federal government's policy on medical marijuana due to being denied treatment by the Department of Veterans Affairs. A ruling that acknowledged Krawitz's standing, but ultimately stood by the DEA was made on January 22, 2013. On December 17, 2009, Rev. Bryan A. Krumm, CNP, filed a rescheduling petition for Cannabis with the DEA arguing that "because marijuana does not have the abuse potential for placement in Schedule I of the CSA, and because marijuana now has accepted medical use in 13 states, and because the DEA's own

title: Removal of cannabis from Schedule I of the Controlled Substances Act
text: right to challenge any incorrect findings by the FDA and/or DEA whether Cannabis should even be regulated under the CSA. On November 30, 2011, Washington State Governor Christine Gregoire announced the filing of a petition with the U.S. Drug Enforcement Administration asking the agency to reclassify marijuana as a Schedule 2 drug, which will allow its use for treatment – prescribed by doctors and filled by pharmacists. Gov. Lincoln Chafee (I-Rhode Island) also signed the petition. On December 23, 2015, Tom Angell reported that the FDA had finally issued a recommendation to the DEA regarding both the 2009 and 2011

title: Removal of cannabis from Schedule I of the Controlled Substances Act
text: their meeting on May 11, 2011 by Kurtis Hanna that he planned on filing for judicial review of the agency's decision. In response, the Board voted to petition the State Legislature to remove the Board's authority to remove substances from Schedule I. At a Conference Committee for Omnibus Drug Bill HF57 on May 18, 2011, the following sentence was added to the bill, "The Board of Pharmacy may not delete or reschedule a drug that is in Schedule I" and the following sentence of statute was deleted, "the state Board of Pharmacy [...] shall annually, on or before May 1

title: Removal of cannabis from Schedule I of the Controlled Substances Act
text: as it has for alcohol. The bill was referred to committee but died when no further action was taken. In August 2016, the DEA rejected calls to reschedule marijuana, but indicated an increase in availability for research. The 2016 platform of the Democratic Party called for removal of marijuana from Schedule I of the Controlled Substances Act, "providing a reasoned pathway for future legalization" of marijuana. This language was approved in a close vote (81-80 vote) in the platform committee. In February 2017, Morgan Griffith, a Virginia Republican, introduced H.R. 714, Legitimate Use of Medicinal Marijuana Act, that would move

title: Cannabis drug testing
text: other drug testing methods. Cannabis is detectable in the blood for approximately 12–24 hours, with heavy/frequent use detectable in the blood for up to 7 days. Because they are invasive and difficult to administer, blood tests are used less frequently. They are typically used in investigations of accidents, injuries and DUIs. Urine contains predominantly THC-COOH, while hair, oral fluid and sweat contain primarily THC. Blood may contain both substances, with the relative amounts dependent on the recency and extent of usage. Though very unlikely to be used, and more unlikely in court, Electroencephalography or EEG shows somewhat more persistent alpha

title: Temporary class drug
text: legally. Products that were on sale immediately prior to the introduction of the Act were allowed to continue to be on sale while the safety testing regime is implemented, but can be removed from sale if significant adverse events are reported. A number of interim licenses have been refused or revoked under this process, and by January 2014 a total of twelve more synthetic cannabis products had been removed from sale, containing ingredients such as ADB-CHMICA (SGT-7), 5F-PB-22, SGT-55 (CUMYL-BICA), SGT-56 (CUMYL-PICA), 4-F-AM-2201, 4-Cl-AM-2201 and PB-22. On 27 April 2014 it was announced that all 41 remaining untested "legal high"

title: Removal of cannabis from Schedule I of the Controlled Substances Act
text: Final Determination on the Petition for Rescheduling on July 8, 2011. The Petition for Writ of Mandamus was subsequently dismissed by the D.C. Circuit Court of Appeals as moot on October 14, 2011. In response to the petition's denial, medical cannabis advocacy group Americans for Safe Access appealed to the D.C. Circuit on January 23, 2012. Oral arguments in the case "Americans for Safe Access v. DEA" were heard on October 16, 2012. On the same day the case was heard, the court ordered the plaintiffs (ASA) to clarify their arguments on standing. In response, ASA filed a supplemental brief

title: Cannabis and impaired driving
text: metabolite "per se" test standard. Testing for metabolites of THC, versus the actual THC intoxicant, can result in DUID convictions of users who aren't actually impaired. According to National Institute on Drug Abuse, "the role played by marijuana in crashes is often unclear because it can be detected in body fluids for days or even weeks after intoxication". Fat solubility of THC also makes detection in body fluids, which are mostly water, problematic, leading to false indication of non-impairment for users. Germany's blood serum (not whole blood like most standards) THC-A limit is 1 ng/mL. In Uruguay, the first nation

title: Removal of cannabis from Schedule I of the Controlled Substances Act
text: medical marijuana. Currently, the FDA is conducting an analysis, at the request of the DEA, on whether marijuana should be downgraded, said Douglas Throckmorton, Deputy Director for Regulatory Programs at the FDA, at a congressional hearing in June 2014. In August 2016 the DEA reaffirmed its position and refused to remove Schedule I classification. However, the DEA announced that it will end restrictions on the supply of marijuana to researchers and drug companies that had previously only been available from the government's own facility at the University of Mississippi. Advocates of marijuana legalization argue that the budgetary impact of removing